A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157Noah M. Hahn, Daniel M. Geynisman, Alex S. Baras et al.|Clinical Cancer Research|2016Cited by 72
Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.Роберто Пили, Noah M. Hahn, David I. Quinn et al.|Journal of Clinical Oncology|2019Cited by 21